The stock of Apyx Medical Corp (APYX) has seen a 24.30% increase in the past week, with a 38.83% gain in the past month, and a -5.00% decrease in the past quarter. The volatility ratio for the week is 13.55%, and the volatility levels for the past 30 days are at 12.27% for APYX. The simple moving average for the past 20 days is 26.65% for APYX’s stock, with a 2.41% simple moving average for the past 200 days.
Is It Worth Investing in Apyx Medical Corp (NASDAQ: APYX) Right Now?
The 36-month beta value for APYX is also noteworthy at 1.05. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for APYX is 32.16M, and at present, short sellers hold a 0.80% of that float. The average trading volume of APYX on May 13, 2025 was 52.10K shares.
APYX) stock’s latest price update
The stock price of Apyx Medical Corp (NASDAQ: APYX) has jumped by 20.36 compared to previous close of 1.11. Despite this, the company has seen a gain of 24.30% in its stock price over the last five trading days. globenewswire.com reported 2025-05-13 that The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System™ (“AYON”).
Analysts’ Opinion of APYX
Stephens, on the other hand, stated in their research note that they expect to see APYX reach a price target of $8. The rating they have provided for APYX stocks is “Overweight” according to the report published on July 14th, 2023.
Lake Street gave a rating of “Buy” to APYX, setting the target price at $12 in the report published on May 20th of the previous year.
APYX Trading at 20.76% from the 50-Day Moving Average
After a stumble in the market that brought APYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.79% of loss for the given period.
Volatility was left at 12.27%, however, over the last 30 days, the volatility rate increased by 13.55%, as shares surge +21.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.52% lower at present.
During the last 5 trading sessions, APYX rose by +21.50%, which changed the moving average for the period of 200-days by -7.80% in comparison to the 20-day moving average, which settled at $1.0486. In addition, Apyx Medical Corp saw -15.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APYX starting from HILL MATTHEW C, who purchase 5,336 shares at the price of $1.13 back on Aug 13 ’24. After this action, HILL MATTHEW C now owns 7,836 shares of Apyx Medical Corp, valued at $6,030 using the latest closing price.
Stock Fundamentals for APYX
Current profitability levels for the company are sitting at:
- -0.36 for the present operating margin
- 0.47 for the gross margin
The net margin for Apyx Medical Corp stands at -0.45. The total capital return value is set at -0.35. Equity return is now at value -130.26, with -30.62 for asset returns.
Based on Apyx Medical Corp (APYX), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at -0.47. The debt to equity ratio resting at 2.73. The interest coverage ratio of the stock is -3.19.
Currently, EBITDA for the company is -16.8 million with net debt to EBITDA at -0.4. When we switch over and look at the enterprise to sales, we see a ratio of 1.07. The receivables turnover for the company is 3.38for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.45.
Conclusion
In summary, Apyx Medical Corp (APYX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
